0001745999false00017459992024-06-052024-06-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 05, 2024

 

 

Beam Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39208

81-5238376

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

238 Main Street

 

Cambridge, Massachusetts

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 327-8775

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

BEAM

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 5, 2024, Beam Therapeutics Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 19, 2024 (the “Proxy Statement”).

 

Proposal 1 – The following nominee was elected as a Class I director to serve on the Company’s board of directors until the Company’s 2027 annual meeting of stockholders, and until his successor has been duly elected and qualified, based on the following votes:

 

Nominee

For

Against

Abstentions

Broker Non-Votes

Graham Cooper

       49,482,793

   6,520,772

1,838,647

8,424,668

 

 

Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024 was ratified, based on the following votes:

 

For

Against

Abstentions

 

66,048,930

176,166

41,784

 

Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes:

 

For

Against

Abstentions

Broker Non-Votes

56,501,513

1,295,311

45,388

8,424,668

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Beam Therapeutics Inc.

 

 

 

 

Date:

June 10, 2024

By:

/s/ John Evans

 

 

 

John Evans
Chief Executive Officer

 

v3.24.1.1.u2
Document And Entity Information
Jun. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2024
Entity Registrant Name Beam Therapeutics Inc.
Entity Central Index Key 0001745999
Entity Emerging Growth Company false
Entity File Number 001-39208
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-5238376
Entity Address, Address Line One 238 Main Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 857
Local Phone Number 327-8775
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol BEAM
Security Exchange Name NASDAQ
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Beam Therapeutics Charts.
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Beam Therapeutics Charts.